IndraLab

Statements

Mitoxantrone activates USP11. 1 / 1

| 1

reach

"87,107,108 Mitoxantrone, a PARPi that targets the USP11 key enzyme that interacts with BRCA2, has been shown to be 40- to 20,000-fold more potent than the current gemcitabine first-line treatment in 2[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

24635863

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Mitoxantrone activates USP11. 1 / 1

INDRA sources:

Databases

Reading